Literature DB >> 22629111

New Treatments for Rhabdomyosarcoma: the Importance of Target Practice.

Frederic G Barr1.   

Abstract

To address the poor outcomes in rhabdomyosarcoma, particularly the alveolar subtype, new therapies are needed. Potential cancer-specific alterations that may be molecular targets include gene fusions or copy number changes. Following the latter strategy, an attractive antigene approach was developed to inhibit MYCN oncogene expression in rhabdomyosarcoma.

Entities:  

Year:  2011        PMID： 22629111      PMCID： PMC3271127          DOI： 10.1158/1078-0432.CCR-11-2832

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

Review 1.  N-myc transcription molecule and oncoprotein.

Authors:  Wayne D Thomas; Anna Raif; Loen Hansford; Glenn Marshall
Journal:  Int J Biochem Cell Biol       Date:  2004-05       Impact factor: 5.085

2.  Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.

Authors:  Roberto Tonelli; Alan McIntyre; Consuelo Camerin; Zoë S Walters; Korinne Di Leo; Joanna Selfe; Stefania Purgato; Edoardo Missiaglia; Andrea Tortori; Jane Renshaw; Annalisa Astolfi; Kathryn R Taylor; Salvatore Serravalle; Ryan Bishop; Cristina Nanni; Linda J Valentijn; Andrea Faccini; Ivo Leuschner; Serena Formica; Jorge S Reis-Filho; Valentina Ambrosini; Khin Thway; Monica Franzoni; Brenda Summersgill; Rosangela Marchelli; Patrizia Hrelia; Giorgio Cantelli-Forti; Stefano Fanti; Roberto Corradini; Andrea Pession; Janet Shipley
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

3.  Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.

Authors:  Gabriela E Mercado; Shujuan J Xia; Chune Zhang; Eun Hyun Ahn; Donna M Gustafson; Marick Laé; Marc Ladanyi; Frederic G Barr
Journal:  Genes Chromosomes Cancer       Date:  2008-06       Impact factor: 5.006

4.  Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  Jennifer L Reichek; Fenghai Duan; Lynette M Smith; Donna M Gustafson; Roddy S O'Connor; Chune Zhang; Mandy J Dunlevy; Julie M Gastier-Foster; Frederic G Barr
Journal:  Clin Cancer Res       Date:  2011-01-10       Impact factor: 12.531

5.  Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype.

Authors:  Daniel Williamson; Yong-Jie Lu; Tony Gordon; Raf Sciot; Anna Kelsey; Cyril Fisher; Christopher Poremba; John Anderson; Kathy Pritchard-Jones; Janet Shipley
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

6.  Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis.

Authors:  Roberto Tonelli; Stefania Purgato; Consuelo Camerin; Raffaele Fronza; Fabrizio Bologna; Simone Alboresi; Monica Franzoni; Roberto Corradini; Stefano Sforza; Andrea Faccini; Jason M Shohet; Rosangela Marchelli; Andrea Pession
Journal:  Mol Cancer Ther       Date:  2005-05       Impact factor: 6.261

7.  Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.

Authors:  Liang Cao; Yunkai Yu; Sven Bilke; Robert L Walker; Linnia H Mayeenuddin; David O Azorsa; Fan Yang; Marbin Pineda; Lee J Helman; Paul S Meltzer
Journal:  Cancer Res       Date:  2010-07-27       Impact factor: 12.701

Review 8.  Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.

Authors:  F G Barr
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

9.  Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  Frederic G Barr; Fenghai Duan; Lynette M Smith; Donna Gustafson; Mandy Pitts; Sue Hammond; Julie M Gastier-Foster
Journal:  Genes Chromosomes Cancer       Date:  2009-08       Impact factor: 5.006

Review 10.  MYCN in neuronal tumours.

Authors:  Manfred Schwab
Journal:  Cancer Lett       Date:  2004-02-20       Impact factor: 8.679
View more
  1 in total

Review 1.  Rhabdomyoblastic Differentiation in Head and Neck Malignancies Other Than Rhabdomyosarcoma.

Authors:  Justin A Bishop; Lester D R Thompson; Antonio Cardesa; Leon Barnes; James S Lewis; Asterios Triantafyllou; Henrik Hellquist; Goran Stenman; Jennifer L Hunt; Michelle D Williams; Pieter J Slootweg; Kenneth O Devaney; Douglas R Gnepp; Bruce M Wenig; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck Pathol       Date:  2015-03-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.